Literature DB >> 17906881

Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease.

Ute Hehr1, Goekhan Uyanik, Claudia Gross, Maggie C Walter, Axel Bohring, Monika Cohen, Barbara Oehl-Jaschkowitz, Lynne M Bird, Ghiat M Shamdeen, Ulrich Bogdahn, Gerhard Schuierer, Haluk Topaloglu, Ludwig Aigner, Hanns Lochmüller, Jürgen Winkler.   

Abstract

Muscle-eye-brain disease (MEB, OMIM 253280) is an autosomal recessive disorder characterized by a distinct triad of congenital muscular dystrophy, structural eye abnormalities, and cobblestone lissencephaly. Clinically, MEB patients present with early onset muscular hypotonia, severely compromised motor development, and mental retardation. Magnetic resonance imaging reveals a lissencephaly type II with hypoplasia of the brainstem and cerebellum. MEB is associated with mutations in the gene for protein O-mannose beta-1,2-N-acetylglucosaminyltransferase (POMGnT1, OMIM 606822). In this paper, we report the clinical findings of nine MEB patients from eight families. Eight of the nine patients presented typical features of MEB. However, a broad phenotypic variability was observed, ranging from two patients with severe autistic features to another patient with an unusually mild phenotype, initially diagnosed as congenital muscular dystrophy. Furthermore, severe hydrocephalus was reported in two families during a previous pregnancy, emphasizing the phenotypic overlap with Walker-Warburg syndrome. In addition to three previously reported mutations, we identified six novel POMGnT1 mutations (one missense, five truncating) in the present patient cohort. Our data suggest mutational hotspots within the minimal catalytic domain at arginine residue 442 (exon 16) and in intron 17. It is interesting to note that all mutations analyzed so far result in a complete loss of enzyme activity. Therefore, we conclude that the type and position of the POMGnT1 mutations are not of predictive value for the clinical severity. This supports the notion that additional environmental and/or genetic factors may contribute to the observed broad spectrum of POMGnT1-associated phenotypes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906881     DOI: 10.1007/s10048-007-0096-y

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  30 in total

1.  POMGnT1 mutation and phenotypic spectrum in muscle-eye-brain disease.

Authors:  C Diesen; A Saarinen; H Pihko; C Rosenlew; B Cormand; W B Dobyns; J Dieguez; L Valanne; T Joensuu; A-E Lehesjoki
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

2.  Deficiency of alpha-dystroglycan in muscle-eye-brain disease.

Authors:  Hiroki Kano; Kazuhiro Kobayashi; Ralf Herrmann; Masaji Tachikawa; Hiroshi Manya; Ichizo Nishino; Ikuya Nonaka; Volker Straub; Beril Talim; Thomas Voit; Haluk Topaloglu; Tamao Endo; Hideki Yoshikawa; Tatsushi Toda
Journal:  Biochem Biophys Res Commun       Date:  2002-03-15       Impact factor: 3.575

3.  Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease.

Authors:  Kiyomi Taniguchi; Kazuhiro Kobayashi; Kayoko Saito; Hideo Yamanouchi; Akira Ohnuma; Yukiko K Hayashi; Hiroshi Manya; Dong Kyu Jin; Munhyang Lee; Enrico Parano; Raffaele Falsaperla; Piero Pavone; Rudy Van Coster; Beril Talim; Alice Steinbrecher; Volker Straub; Ichizo Nishino; Haluk Topaloglu; Thomas Voit; Tamao Endo; Tatsushi Toda
Journal:  Hum Mol Genet       Date:  2003-03-01       Impact factor: 6.150

4.  Muscle-eye-brain disease: clinical features, visual evoked potentials and brain imaging in 20 patients.

Authors:  P Santavuori; L Valanne; T Autti; M Haltia; H Pihko; K Sainio
Journal:  Eur J Paediatr Neurol       Date:  1998       Impact factor: 3.140

5.  Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1.

Authors:  A Yoshida; K Kobayashi; H Manya; K Taniguchi; H Kano; M Mizuno; T Inazu; H Mitsuhashi; S Takahashi; M Takeuchi; R Herrmann; V Straub; B Talim; T Voit; H Topaloglu; T Toda; T Endo
Journal:  Dev Cell       Date:  2001-11       Impact factor: 12.270

6.  A new mutation of the fukutin gene in a non-Japanese patient.

Authors:  Fatma Silan; Mieko Yoshioka; Kazuhiro Kobayashi; Enver Simsek; Murat Tunc; Murat Alper; Meryem Cam; Aysel Guven; Yoji Fukuda; Moritoshi Kinoshita; Kenan Kocabay; Tatsushi Toda
Journal:  Ann Neurol       Date:  2003-03       Impact factor: 10.422

7.  Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality.

Authors:  Tobias Willer; Belén Prados; Juan Manuel Falcón-Pérez; Ingrid Renner-Müller; Gerhard K H Przemeck; Mark Lommel; Antonio Coloma; M Carmen Valero; Martin Hrabé de Angelis; Widmar Tanner; Eckhard Wolf; Sabine Strahl; Jesús Cruces
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

8.  MRI of the brain in muscle-eye-brain (MEB) disease.

Authors:  L Valanne; H Pihko; K Katevuo; P Karttunen; H Somer; P Santavuori
Journal:  Neuroradiology       Date:  1994-08       Impact factor: 2.804

9.  Loss-of-function of an N-acetylglucosaminyltransferase, POMGnT1, in muscle-eye-brain disease.

Authors:  Hiroshi Manya; Keiwa Sakai; Kazuhiro Kobayashi; Kiyomi Taniguchi; Masao Kawakita; Tatsushi Toda; Tamao Endo
Journal:  Biochem Biophys Res Commun       Date:  2003-06-20       Impact factor: 3.575

10.  An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy.

Authors:  K Kobayashi; Y Nakahori; M Miyake; K Matsumura; E Kondo-Iida; Y Nomura; M Segawa; M Yoshioka; K Saito; M Osawa; K Hamano; Y Sakakihara; I Nonaka; Y Nakagome; I Kanazawa; Y Nakamura; K Tokunaga; T Toda
Journal:  Nature       Date:  1998-07-23       Impact factor: 49.962

View more
  19 in total

1.  Mutations in POMGNT1 cause non-syndromic retinitis pigmentosa.

Authors:  Mingchu Xu; Takeyuki Yamada; Zixi Sun; Aiden Eblimit; Irma Lopez; Feng Wang; Hiroshi Manya; Shan Xu; Li Zhao; Yumei Li; Adva Kimchi; Dror Sharon; Ruifang Sui; Tamao Endo; Robert K Koenekoop; Rui Chen
Journal:  Hum Mol Genet       Date:  2016-01-28       Impact factor: 6.150

Review 2.  The o-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy.

Authors:  Lance Wells
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

Review 3.  Glycan susceptibility factors in autism spectrum disorders.

Authors:  Chrissa A Dwyer; Jeffrey D Esko
Journal:  Mol Aspects Med       Date:  2016-07-11

4.  Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalus.

Authors:  Sheng Chih Jin; Weilai Dong; Adam J Kundishora; Shreyas Panchagnula; Andres Moreno-De-Luca; Charuta G Furey; August A Allocco; Rebecca L Walker; Carol Nelson-Williams; Hannah Smith; Ashley Dunbar; Sierra Conine; Qiongshi Lu; Xue Zeng; Michael C Sierant; James R Knight; William Sullivan; Phan Q Duy; Tyrone DeSpenza; Benjamin C Reeves; Jason K Karimy; Arnaud Marlier; Christopher Castaldi; Irina R Tikhonova; Boyang Li; Helena Perez Peña; James R Broach; Edith M Kabachelor; Peter Ssenyonga; Christine Hehnly; Li Ge; Boris Keren; Andrew T Timberlake; June Goto; Francesco T Mangano; James M Johnston; William E Butler; Benjamin C Warf; Edward R Smith; Steven J Schiff; David D Limbrick; Gregory Heuer; Eric M Jackson; Bermans J Iskandar; Shrikant Mane; Shozeb Haider; Bulent Guclu; Yasar Bayri; Yener Sahin; Charles C Duncan; Michael L J Apuzzo; Michael L DiLuna; Ellen J Hoffman; Nenad Sestan; Laura R Ment; Seth L Alper; Kaya Bilguvar; Daniel H Geschwind; Murat Günel; Richard P Lifton; Kristopher T Kahle
Journal:  Nat Med       Date:  2020-10-19       Impact factor: 53.440

5.  Homozygous dystroglycan mutation associated with a novel muscle-eye-brain disease-like phenotype with multicystic leucodystrophy.

Authors:  Tobias Geis; Klaus Marquard; Tanja Rödl; Christof Reihle; Sophie Schirmer; Thekla von Kalle; Antje Bornemann; Ute Hehr; Markus Blankenburg
Journal:  Neurogenetics       Date:  2013-09-20       Impact factor: 2.660

6.  Using whole-exome sequencing to identify inherited causes of autism.

Authors:  Timothy W Yu; Maria H Chahrour; Michael E Coulter; Sarn Jiralerspong; Kazuko Okamura-Ikeda; Bulent Ataman; Klaus Schmitz-Abe; David A Harmin; Mazhar Adli; Athar N Malik; Alissa M D'Gama; Elaine T Lim; Stephan J Sanders; Ganesh H Mochida; Jennifer N Partlow; Christine M Sunu; Jillian M Felie; Jacqueline Rodriguez; Ramzi H Nasir; Janice Ware; Robert M Joseph; R Sean Hill; Benjamin Y Kwan; Muna Al-Saffar; Nahit M Mukaddes; Asif Hashmi; Soher Balkhy; Generoso G Gascon; Fuki M Hisama; Elaine LeClair; Annapurna Poduri; Ozgur Oner; Samira Al-Saad; Sadika A Al-Awadi; Laila Bastaki; Tawfeg Ben-Omran; Ahmad S Teebi; Lihadh Al-Gazali; Valsamma Eapen; Christine R Stevens; Leonard Rappaport; Stacey B Gabriel; Kyriacos Markianos; Matthew W State; Michael E Greenberg; Hisaaki Taniguchi; Nancy E Braverman; Eric M Morrow; Christopher A Walsh
Journal:  Neuron       Date:  2013-01-23       Impact factor: 17.173

7.  Novel POMGnT1 mutations cause muscle-eye-brain disease in Chinese patients.

Authors:  Hui Jiao; Hiroshi Manya; Shuo Wang; Yanzhi Zhang; Xiaoqing Li; Jiangxi Xiao; Yanling Yang; Kazuhiro Kobayashi; Tatsushi Toda; Tamao Endo; Xiru Wu; Hui Xiong
Journal:  Mol Genet Genomics       Date:  2013-05-21       Impact factor: 3.291

Review 8.  The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy.

Authors:  Jamie L Marshall; Yukwah Kwok; Brian J McMorran; Linda G Baum; Rachelle H Crosbie-Watson
Journal:  FEBS J       Date:  2013-05-13       Impact factor: 5.542

Review 9.  O-Mannosylation and human disease.

Authors:  Christina M Dobson; Samuel J Hempel; Stephanie H Stalnaker; Ryan Stuart; Lance Wells
Journal:  Cell Mol Life Sci       Date:  2012-11-01       Impact factor: 9.261

10.  Neuropathology of genetically defined malformations of cortical development-A systematic literature review.

Authors:  Stefanie Brock; Filip Cools; Anna C Jansen
Journal:  Neuropathol Appl Neurobiol       Date:  2021-02-14       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.